TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00915200

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 600 mg orally twice daily for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 600 mg orally twice daily for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 600 mg orally twice daily for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: silibin
Description: 480 mg orally twice daily for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: silibin
Description: 480 mg orally twice daily for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high-dose silibin
Description: 960 mg orally twice daily for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcysteine placebo
Description: excipient orally twice daily for three months
Study: NCT04340141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection
Description: Undergo surgical resection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02742493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.028 bonded to canines
Description: lower fixed canine and canine retainer (0.028 stainless steel bonded to canines) and upper removable Hawley (Intervention A)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.027 7-strand bonded to all 6
Description: lower fixed canine to canine retainer (7-strand Twistflex 0.027 bonded to all six anterior teeth) and upper removable Hawley (Intervention B)
Study: NCT00915200

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine placebo
Description: excipient orally twice daily for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: silibin placebo
Description: excipient orally twice daily for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: silibin placebo
Description: excipient orally twice daily for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: silibin placebo
Description: excipient orally twice daily for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: silibin placebo
Description: excipient orally twice daily for three months
Study: NCT00533078

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: omegaven
Description: Trial participants are prescribed TPN by the attending physician as soon as indicated, which will be administered via a central venous line over a time period of approximately 20 hours per day. The formulation given to all patients is Nutriflex lipid spezial®, an emulsion containing the full supply of carbohydrates, amino acids and lipids (SO:MCT = 1:1) with a total energy content of 2215 kcal in a 1875 ml volume, see Investigator's Brochure. In addition, they receive daily infusional Omegaven® 100 ml over 4 hours, which equal FO 10 g/d or omega-3 PUFA 3-6 g/d.
Study: NCT01851850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opicapone
Description: 25mg or 50mg once per day
Study: NCT02742493

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: removable Hawley-type
Description: lower Hawley-type and upper Hawley removable retainer (Control)
Study: NCT02642978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RSRCLM
Description: The Da Vinci Surgical System may help to overcome some of the difficulties of laparoscopy for complicated abdominal surgery. The aim of this study was to present an innovative technique that is robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open
Description: Traditional open simultaneous radical resection of both colorectal cancer and liver metastasis
Study: NCT02872454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: Each week, enrolled participants will receive daily text messages from one of three randomly assigned psychotherapeutic modalities-cognitive restructuring, behavioral activation, and techniques based on Acceptance and Commitment Therapy (ACT)-for a total of 12 weeks. The messages were developed, reviewed, and refined by a multidisciplinary team of experienced therapists, including social workers, psychologists, and psychiatrists.
Study: NCT02161562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: 150mg omalizumab via sub-cutaneous injection once every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: 300mg omalizumab via sub-cutaneous injection once every 4 weeks
Study: NCT01394705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BodyMedia
Description: Accelerometer
Study: NCT02750787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Study Product
Description: Two 220 ml servings per day
Study: NCT04400474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg
Description: All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
Study: NCT02995304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine premedication
Description: 30 children will 0.1 mg/kg morphine as a premedication 20 to 30 min before surgical incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam premedication
Description: All children who will receive 0.025 mg/kg midazolam IV as a premedication 20 to 30 min before surgical incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam premedication
Description: All children who will receive 0.025 mg/kg midazolam IV as a premedication 20 to 30 min before surgical incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline premedication (placebo)
Description: 30 children in midazolam only group will receive saline after midazolam
Study: NCT03344666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 1 Treatment BI+HC
Description: Participants in the Brief intervention + Health Coach (BI+HC) will receive a BI in the ED, followed by weekly sessions with the Health Coach for 4 weeks, which will occur by phone or in person. During sessions, the HC will review the prior week's progress, and discuss goals and plans for the following week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 1 Treatment BI+TM
Description: Participants in the Brief intervention + Text messages (BI+TM) will receive a BI in the ED, followed by daily TMs for 4 weeks. TM's are tailored based on weekly surveys and focus on motives for alcohol and violence and strategies to reduce involvement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 2 Treatment Responders
Description: Participants in the BI+HC assigned to stay the course (e.g., continue to receive the HC) will have 4 more weekly sessions with the HC.~Participants in the BI+TM assigned to stay the course (e.g., continue to receive the TM) will receive 4 more weeks of TM.~Participants in the BI+HC or BI+TM assigned to stepped down control will receive a brochure containing community resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 2 Treatment Non-Responders
Description: Participants in the BI+HC assigned to be stepped up will receive HC+, which will consist of weekly sessions as well as on daily TMs from the HC.~Participants in the BI+HC assigned to stay the course (e.g., continue to receive the HC) will have 4 more weekly sessions with the HC.~Participants in the BI+TM assigned to be stepped up will receive the HC, which consists of 4 weekly sessions with the HC.~Participants in the BI+TM assigned to stay the course (e.g., continue to receive the TM) will receive 4 more weeks of TM.
Study: NCT03616431

Intervention type: DIAGNOSTIC_TEST
Intervention: Pancreo-KIT breath test
Description: Pancreo-Kit (Isomed Pharma, Madrid, Spain) is a breath test devised to measure Pancreatic Enzyme Insufficiency. It is a non-invasive method to obtain information about the digestion of consumed lipids; this in turn is informative about the exocrine enzyme activity of the pancreas (specifically pancreatic lipase). This kit is manufactured to EC directive 98/79/EEC and carries the CE mark.~The test is based on measurement of 13C which is a stable naturally occurring environmental isotope of carbon with a nucleus containing 6 protons and 7 neutrons (note, it is not radioactive).
Study: NCT04845412

Intervention type: DIAGNOSTIC_TEST
Intervention: Hearing screening tests
Description: Our study was conducted in accordance with the National Hearing Screening Test Protocol. The newborns had transient evoked otoacoustic emissions (TEOAE) with click stimulus as a hearing screening test in the first three days after birth, using Otometrics Madsen Accuscreen S/N: 36484 (USA) device.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hearing screening tests
Description: Our study was conducted in accordance with the National Hearing Screening Test Protocol. The newborns had transient evoked otoacoustic emissions (TEOAE) with click stimulus as a hearing screening test in the first three days after birth, using Otometrics Madsen Accuscreen S/N: 36484 (USA) device.
Study: NCT00648167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric citrate
Description: ferric citrate will be provided as a 375mg capsule. Dosing and frequency are dependent on patient's serum phosphorus levels. Dosing will occur over the 28-day study.
Study: NCT02828410

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SBI
Description: Serum bovine immunoglobulin protein isolate 10 g twice per day
Study: NCT02735629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX1739 - 300 mg
Description: Ampakine CX1739 - 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX1739 - 600 mg
Description: CX1739 - 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX1739 - 900 mg
Description: CX1739 - 900 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to 300 mg CX1739
Study: NCT02342405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 80% oxygen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 30% oxygen
Study: NCT01895127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunoglobulin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasmapheresis
Study: NCT00157612

Intervention type: PROCEDURE
Group type: OTHER
Intervention: a clinical pathway nursing home acquired pneumonia
Description: treatment in nursing homes according to a clinical pathway, which included use of oral anti-microbials, portable chest radiographs, oxygen saturation monitoring, rehydrations and close monitoring by research nurse
Study: NCT00119158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of pimecrolimus and fluticasone
Description: Pimecrolimus cream twice a day and fluticasone cream once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pimecrolimus
Description: apply daily with fluticasone cream for flares

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pimecrolimus
Description: apply daily with fluticasone cream for flares
Study: NCT01043757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives for increasing physical exercise
Description: Throughout the 12-week intervention, participants will receive step goals. The step goals will increase by 250 steps per week, The intervention will last a total of 12 weeks. After each seven-day week, step goals will increase by an additional 250 steps - thus over the 12 weeks, participants will be asked to increase their daily step count by 3,000. Participants will receive financial incentives to attain these step goals; the incentive schemes differ according to intervention arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives for increasing physical exercise
Description: Throughout the 12-week intervention, participants will receive step goals. The step goals will increase by 250 steps per week, The intervention will last a total of 12 weeks. After each seven-day week, step goals will increase by an additional 250 steps - thus over the 12 weeks, participants will be asked to increase their daily step count by 3,000. Participants will receive financial incentives to attain these step goals; the incentive schemes differ according to intervention arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives for increasing physical exercise
Description: Throughout the 12-week intervention, participants will receive step goals. The step goals will increase by 250 steps per week, The intervention will last a total of 12 weeks. After each seven-day week, step goals will increase by an additional 250 steps - thus over the 12 weeks, participants will be asked to increase their daily step count by 3,000. Participants will receive financial incentives to attain these step goals; the incentive schemes differ according to intervention arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives for increasing physical exercise
Description: Throughout the 12-week intervention, participants will receive step goals. The step goals will increase by 250 steps per week, The intervention will last a total of 12 weeks. After each seven-day week, step goals will increase by an additional 250 steps - thus over the 12 weeks, participants will be asked to increase their daily step count by 3,000. Participants will receive financial incentives to attain these step goals; the incentive schemes differ according to intervention arm.
Study: NCT03429946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Participants will receive spironolactone 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglycemic Hyperinsulinemic Clamp
Description: Participants undergo two 120-minute hypoglycemic (50 mg/dL) hyperinsulinemic clamps - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglycemic Hyperinsulinemic Clamp
Description: Participants undergo two 120-minute hypoglycemic (50 mg/dL) hyperinsulinemic clamps - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Euglycemic Hyperinsulinemic Clamp
Description: Participants undergo two 120-minute euglycemic (90 mg/dL) hyperinsulinemic clamps - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit.Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
Study: NCT00276575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study: NCT02760082

Intervention type: OTHER
Intervention: Qualitative evaluation

Intervention type: OTHER
Intervention: Qualitative evaluation

Intervention type: OTHER
Intervention: Qualitative evaluation
Study: NCT03373565

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial
Description: Coronary angiography using radial approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palmar
Description: Coronary angiography using radial approach
Study: NCT02424838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA of pancreatic masses
Description: EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA of pancreatic masses
Description: EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA of pancreatic masses
Description: EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA of pancreatic masses
Description: EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22 gauge needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22 gauge needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 25 gauge needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 25 gauge needle
Study: NCT02910245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine (Purinethol)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mesalamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Study: NCT00634569

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flebogamma 5% DIF
Description: Intravenous Immune Globulin (Human)
Study: NCT02101970

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Description: Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet and Exercise
Description: Increasing physical activity required over 6 month period to be tracked by a Fitbit. Diet based on caloric intake and eating approved foods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Exercise
Description: Increasing physical activity required over 6 month period to be tracked by a Fitbit. Diet based on caloric intake and eating approved foods.
Study: NCT01166451

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-iron formula
Description: Infants randomly assigned at 6 months of age to receive low-iron formula (average 2.3 mg/L, range 1.6 - 2.4 mg/L) until 12 months of age. Low-iron formula distributed in powdered form. Project personnel visited infants' homes weekly to record measures of powdered formula used per day. Formula consumption was also verified by the number of cans given by the clinic nurse at each visit (regular pediatric visits and monthly clinic appointments until 12 months of age.)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-iron formula
Description: Infants randomly assigned at 6 months of age to receive high-iron formula (average 12.7 mg/L) until 12 months of age. High-iron formula distributed in powdered form. Project personnel visited infants' homes weekly to record measures of powdered formula used per day. Formula consumption was also verified by the number of cans given by the clinic nurse at each visit (regular pediatric visits and monthly clinic appointments until 12 months of age.)
Study: NCT02548026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Eating Frequency (High EF)
Description: Free-living participants complete a 21-day high eating frequency (high EF) Phase in which they consume all daily energy at 8 eating occasions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Eating Frequency (Low EF)
Description: Free-living participants complete a 21-day low eating frequency (low EF) Phase in which they consume all daily energy at 3 eating occasions.
Study: NCT01912209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Everyday Health
Description: MyEveryday Health is a web-based nutritional and lifestyle management program. The program includes personalized diet and weight guidance, meal planners, shopping list generator, recipe finder, weight tracker and dining out and fast food guides. Based on specific algorithms, tips and suggestions on how to make changes in their diet and lifestyle will be give each time the subject logs in. The MyEverydayHealth website will also be available as an app for their smart phone to the participants. If they choose to use the app, daily reminders to log in and use their tools will be sent, along with motivating tool/tips/tricks to stay with the program.